India, Aug. 19 -- Edesa Biotech, Inc. (EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced on Wednesday that it has commenced an underwritten public offering of its common shares, or pre-funded warrants in lieu thereof, along with accompanying warrants to purchase common shares.
The company did not disclose the size, pricing or expected proceeds of the offering. Edesa expects to grant underwriters a 30-day option to purchase additional common shares, or pre-funded warrants, and accompanying warrants representing up to 15% of the total securities offered.
The company intends to use the net proceeds for general corporate purposes, including working ca...